FUSN

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-13.7M ExitQ2 2024 $14M -- --
BlackRockInvestor $-11.0M ExitQ2 2024 $11M -- --
Paul Tudor Jones IITudor Investment $-1.8M ExitQ2 2024 $1.8M -- --
Paul Tudor Jones IITudor Investment $-1.8M ExitQ2 2024 $1.8M -- --
Mario GabelliGAMCO Investors $-244.1K ExitQ2 2024 $244k -- --
Mario GabelliGAMCO Investors $-244.1K ExitQ2 2024 $244k -- --

News

marketwatch.comTrump administration backs nuclear fusion — as a company tied to Trump invests in itmarketwatch.comMay 18

Trade FUSN

About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.

CEO: John F. Valliant
IPO Date: Jun 26, 2020

Market Data

Open: $21.55
High: $21.58
Low: $21.48
Volume: 6.1M
52W High: $21.60
52W Low: $2.31

Valuation

Market Cap: $1.8B
Enterprise Value: $1.8B

Financials

Free Cash Flow: $-86M
Revenue: $2.1M
Net Income: $-95M
Cash: $62M
Debt: $50M

Events

EarningsMay 7

EPS est. -0.38 · actual -0.4